American Society of Hematology

Figure 2

$Figure 2. Cancer clonal fraction. The cancer clonal fraction (CCF) for somatic single-nucleotide variants in 7 genes that were mutated in at least 4 patients at presentation (top) and/or relapse (bottom) is depicted. In addition, a density plot for the cancer clonal fraction for all other nonsilent mutations (presentation: blue, relapse: red) is presented for each patient. Variant allele frequencies and copy numbers used for the calculation of CCFs were derived from whole-exome sequencing data. To describe changes in more detail, we classified clones containing these mutations as minor (<20% CCF), prominent (<60% CCF), or major (≥60% CCF) and called mutations with a CCF ≥90% clonal. Patients are ordered according to events: (S)election of subclonal mutation(s), (A)cquisition of a new SNV at relapse, (L)oss of a SNV at relapse, (M)ovement from one clonal classification to another, and (N)o changes.$

Cancer clonal fraction. The cancer clonal fraction (CCF) for somatic single-nucleotide variants in 7 genes that were mutated in at least 4 patients at presentation (top) and/or relapse (bottom) is depicted. In addition, a density plot for the cancer clonal fraction for all other nonsilent mutations (presentation: blue, relapse: red) is presented for each patient. Variant allele frequencies and copy numbers used for the calculation of CCFs were derived from whole-exome sequencing data. To describe changes in more detail, we classified clones containing these mutations as minor (<20% CCF), prominent (<60% CCF), or major (≥60% CCF) and called mutations with a CCF ≥90% clonal. Patients are ordered according to events: (S)election of subclonal mutation(s), (A)cquisition of a new SNV at relapse, (L)oss of a SNV at relapse, (M)ovement from one clonal classification to another, and (N)o changes.

This Feature Is Available To Subscribers Only